AstraZeneca Expands Immuno-Oncology Collaboration with Innate Pharma
By Jasmine Kalsi & Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 30 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2374 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Revitalising its immuno-oncology portfolio, AstraZeneca (AZ) has expanded its 2015 research collaboration with Innate Pharma following promising Phase II data, in to a three-part deal that will see AZ hand over US$170 M in opt-in and upfront payments and commit up to US$5...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS